A total of 599 and 604 patients received etravirine and placebo, respectively (median treatment duration 96.0 and 69.6 weeks, respectively). There was no significant difference between the treatment groups in the frequency of neuropsychiatric CP 690550 AEs. However, a significant difference in the frequency of rash was observed (20.5% vs. 11.8%, respectively; P < 0.0001); rash was generally mild

to moderate in severity; the rate of discontinuation because of rash was low (2.2% vs. 0% in the etravirine and placebo groups, respectively). The frequency of hepatic AEs was low and similar between the treatment groups (8.7% vs. 7.1%, respectively; P = 0.3370); hepatic enzyme levels did not increase over time. Lipid-related laboratory abnormalities and changes over time in lipid levels were generally comparable between treatment groups. Adjusting for treatment exposure, the frequency of AEs remained similar between treatment groups, with PLX4032 cost the exception of rash [13.7 vs. 9.3 per 100 PYE; relative risk (95% confidence interval) 1.48 (1.02–1.95)]. The frequency of AEs of interest was generally

similar between the treatment groups, both overall and when adjusted for treatment exposure, with the exception of rash which was more frequent in the etravirine group. The nonnucleoside reverse transcriptase inhibitor (NNRTI) etravirine, which has activity against both wild-type HIV and NNRTI-resistant HIV mutants in vitro [1, 2], has demonstrated durable virological and immunological efficacy in treatment-experienced patients with NNRTI resistance in the phase III TMC125 DUET (Demonstrate Undetectable viral load in patients Experienced with ARV Therapy) trials [3, 4]. The overall safety profile of etravirine over 96 weeks, along with safety results in patients coinfected with hepatitis B and/or C virus, has previously been reported [4, 5]. Similar to results reported at week 48, etravirine displayed a tolerability profile at week 96 that was generally similar to that of placebo, with the

exception of rash, which occurred at a higher frequency in the etravirine group [4]. While overall safety data from the week 96 analysis have previously been reported Progesterone [4], there has been no analysis of the potential effect of differential treatment exposure on these findings. In addition, only minimal overall findings have been previously reported on adverse events (AEs) and laboratory abnormalities of interest. AEs of interest are those events thought to be potentially associated with the investigational compound or class, or with the relevant disease state, or that have been identified as important, based on data from earlier studies. They represent an emerging and ever more important aspect of the characterization of the safety profile of a compound during its development and post-marketing follow-up.